Calithera Biosciences (NASDAQ:CALA) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a note issued to investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Calithera Biosciences Price Performance

Shares of Calithera Biosciences stock opened at $0.05 on Friday. Calithera Biosciences has a 1 year low of $0.05 and a 1 year high of $13.38. The business has a 50-day moving average of $0.22 and a two-hundred day moving average of $1.82. The company has a market capitalization of $243,500.00, a P/E ratio of 0.00 and a beta of 1.22.

Insider Buying and Selling

In related news, Director Deepika Pakianathan sold 121,333 shares of the stock in a transaction that occurred on Friday, January 27th. The stock was sold at an average price of $0.39, for a total transaction of $47,319.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.60% of the stock is owned by corporate insiders.

Institutional Trading of Calithera Biosciences

A number of hedge funds have recently made changes to their positions in CALA. Goldman Sachs Group Inc. lifted its position in shares of Calithera Biosciences by 143.2% in the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 72,865 shares during the last quarter. TSP Capital Management Group LLC lifted its holdings in Calithera Biosciences by 18.0% during the 3rd quarter. TSP Capital Management Group LLC now owns 62,900 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 9,605 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Calithera Biosciences by 13.8% during the 3rd quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company’s stock worth $337,000 after purchasing an additional 13,855 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in Calithera Biosciences during the 1st quarter worth approximately $404,000. Finally, Affinity Asset Advisors LLC acquired a new stake in Calithera Biosciences during the 1st quarter worth approximately $404,000. 33.73% of the stock is owned by institutional investors and hedge funds.

About Calithera Biosciences

(Get Rating)

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.